LX1001, a one-time gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, raised levels of the protective APOE2 protein in the cerebrospinal fluid (CSF), early data from an ongoing Phase 1/2 trial shows. Findings in a first patient group treated at low dose also showed the gene therapy reduced the levels of tau protein — a hallmark of Alzheimer’s. No serious adverse events have been reported, supporting the therapy’s safety. The Phase 1/2 trial (NCT03634007), underway in…
You must be logged in to read/download the full post.
The post Gene Therapy LX1001 Showing Potential to Lower Tau Levels in Phase 1 Trial appeared first on BioNewsFeeds.